Association of CYP24A1 with survival and drug resistance in clinical cancer patients: a meta-analysis

Zeng R 1 , Li H 1 , Jia L 2 , Lee SH 3 , Jiang R 1 , Zhang Y 1 Show all authors , Hu X 1 , Ye T 1 , Wang X 1 , Yan X 1 , Lu Y 4 , Sun Z 1 , Xu J 5 , Xu W 6

Affiliations 

  • 1 School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai, China
  • 2 ZJU-UoE Institute, Zhejiang University School of Medicine, Zhejiang University, Haining, China
  • 3 School of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Lakeside CampusSelangor, Malaysia
  • 4 Department of Oncology and Institute of Traditional Chinese Medicine in, Oncology, , Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
  • 5 School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai, China. xjt@fudan.edu.can
  • 6 School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai, China. wei-xu11@tsinghua.org.cn
BMC Cancer, 2022 Dec 16;22(1):1317.
PMID: 36527000 DOI: 10.1186/s12885-022-10369-x

Abstract

BACKGROUND: Acquired chemo-drug resistance constantly led to the failure of chemotherapy for malignant cancers, consequently causing cancer relapse. Hence, identifying the biomarker of drug resistance is vital to improve the treatment efficacy in cancer. The clinical prognostic value of CYP24A1 remains inconclusive, hence we aim to evaluate the association between CYP24A1 and the drug resistance in cancer patients through a meta-analysis approach.

METHOD: Relevant studies detecting the expression or SNP of CYP24A1 in cancer patients up till May 2022 were systematically searched in four common scientific databases including PubMed, EMBASE, Cochrane library and ISI Web of Science. The pooled hazard ratios (HRs) indicating the ratio of hazard rate of survival time between CYP24A1high population vs CYP24A1low population were calculated. The pooled HRs and odds ratios (ORs) with 95% confidence intervals (CIs) were used to explore the association between CYP24A1's expression or SNP with survival, metastasis, recurrence, and drug resistance in cancer patients.

RESULT: Fifteen studies were included in the meta-analysis after an initial screening according to the inclusion and exclusion criteria. There was a total of 3784 patients pooled from all the included studies. Results indicated that higher expression or SNP of CYP24A1 was significantly correlated with shorter survival time with pooled HRs (95% CI) of 1.21 (1.12, 1.31), metastasis with pooled ORs (95% CI) of 1.81 (1.11, 2.96), recurrence with pooled ORs (95% CI) of 2.14 (1.45, 3.18) and drug resistance with pooled HRs (95% CI) of 1.42 (1.17, 1.68). In the subgroup analysis, cancer type, treatment, ethnicity, and detection approach for CYP24A1 did not affect the significance of the association between CYP24A1 expression and poor prognosis.

CONCLUSION: Findings from our meta-analysis demonstrated that CYP24A1's expression or SNP was correlated with cancer progression and drug resistance. Therefore, CYP24A1 could be a potential molecular marker for cancer resistance.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications